Scientific Online Resource System

Varna Medical Forum

The role of RIPK3 in the process of necroptosis in malignant tumors

Nevena Yanulova


Necroptosis is an alternative form of regulated cell death, combining features that apply to both apoptosis and necrosis processes. There is evidence that it is involved in regulating the balance of various cell lineages, organ formation during embryonic development, and tissue homeostasis in adults. Necroptosis plays an essential role in a number of disease processes, such as neurodegenerative diseases, myocardial ischemia, Gaucher's disease, and the progression and metastasis of a number of malignant neoplasms. The process of necroptosis can be triggered by various stimuli such as TNFα, interferon γ, lipopolysaccharides, etc. Receptor-interacting proteins (RIPKs) are serine/threonine kinases known as regulators of cell survival and death. The essence of necroptosis is in the formation of a necrosome consisting of RIPK1, RIPK3, and MLKL. The protumor and antitumor functions of necroptosis are associated with the secretion of various mediators and the initiation of an inflammatory response. Clarifying the role of necroptosis in different types of tumors would contribute to obtaining valuable information, increasing the possibilities for pharmacological influence on malignant tumors, and addressing cases of therapeutic resistance.


necroptosis, RIPK1, RIPK3, malignant tumors

Full Text


Amin P, Florez M, Najafov A, Pan H, Geng J, Ofengeim D et al. Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFalpha-mediated apoptosis. Proc Natl Acad Sci. 2018; 115:E5944–E5953.

Ando Y, Ohuchida K, Otsubo Y, Kibe S, Takesue S, Abe T et al. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS ONE. 2020;15:e0228015.

Ashkenazi A, Dixit V. Death receptors: signaling and modulation. Science. 1998; 28;281(5381):1305-8.

Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001; 11: 372–377.

Chan F, Luz N, Moriwaki K. Programmed necrosis in the cross talk of cell death and inflammation. Annu Rev Immunol.2015; 33, 79–106.

Chen J, Kos R, Garssen J and Redegeld F. Molecular Insights into the Mechanism of Necroptosis: The Necrosome as а Potential Therapeutic Target. Cells.2019; 8, 1486.

Csomos R, Brady G, Duckett C. Enhanced cytoprotective effects of the inhibitor of apoptosis protein cellular IAP1 through stabilization with TRAF2. J Biol Chem. 2009; 284, 20531–20539.

Degterev A, Huang, Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol.2005;1:112–119.

Degterev A, Ofengeim D and Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. 2019; 116(20):9714-9722.

Dhuriya Y, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. Journal of Neuroinflammation. 2018; 199.

Dondelinger Y, Jouan-Lanhouet S, Divert T, Theatre E, Bertin J, Gough P et al. NF-kappaB-Independent Role of IKKalpha/IKKbeta in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling. Mol Cell. 2015; 60, 63–76.

Duprez L, Bertrand M, Vanden Berghe T, Dondelinger Y, Festjens N, Vandenabeele P. Intermediate domain of receptor-interacting protein kinase 1 (RIPK1) determines switch between necroptosis and RIPK1 kinase-dependent apoptosis. J Biol Chem. 2012;287:14863–14872.

Feng S, Yang Y, Mei Y, Ma L, Zhu D, Hoti N et al. Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell Signal. 2007; 19, 2056–2067.

Galluzzi L, Maiuri M, Vitale I, Zischka H, Castedo M, Zitvogel L et al. Cell death modalities: Classification and pathophysiological implications. Cell Death Differ.2007;14:1237–1243.

He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell. 2009; 137, 1100–1111.

Hsu H, Huang J, Shu H, Baichwal V, Goeddel D. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity.1996;4:387–396.

Karin M, Cao Y, Greten F, Li ZW. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002: 2, 301–310.

Kasof G, Prosser J, Liu D, Lorenzi M, Gomes B. The RIP-like kinase, RIP3, induces apoptosis and NF-κB nuclear translocation and localizes to mitochondria. FEBS Letters. 2000; 3: 285-291.

Kim J, Chung J-Y, Park Y, Jang S, Kim H, Choi C-M et al.Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2020; 12(6): 1496.

Koo G, Morgan M, Lee D, Kim W, Yoon J, Koo J et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015; 25(6):707–725.

Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem. 2006; 281, 13636–13643.

Liu S, Joshi K, Denning M, Zhang J. RIPK3 signaling and its role in the pathogenesis of cancers. Cell Mol Life Sci. 2021; 78(23): 7199–7217.

Liu X, Zhou M, Mei L, Ruan J, Hu Q, Peng J et al. Key roles of necroptotic factors in promot-ing tumor growth. Oncotarget. 2016; 7(16):22219–22233.

Liu X, Xie X, Ren Y, Shao Z, Zhang N, Li L et al. The role of necroptosis in disease and treatment. MedComm.2021; 2(4): 730–755.

Luedde М, Lutz М, Carter N, Sosna J, Jacoby C, Vucur M et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodeling after myocardial infarction. Cardiovasc Res. 2014; 103(2):206-16.

Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30(3):151-9.

Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003; 114, 181–190.

Murphy J, Czabotar P, Hildebrand J, Lucet I, Zhang J-G, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39:443–53.

Roychowdhury S, McMullen M, Pisano S, Liu X, Nagy L. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology.2013; 57: 1773-1783.

Seo J, Lee E, Sung H, Seong D, Dondelinger Y, Shin J et al. CHIP controls necroptosis through ubiquitylation- and lysosome-dependent degradation of RIPK3. Nat Cell Biol. 2016;18:291–302.

Shan B, Pan H, Najafov A and Yuan J. Necroptosis in development and diseases. Genes & Dev.2018; 32: 327-340.

Sikora Е. Activation-induced and damage-induced cell death in aging human T cells. Science Direct. 2015; 151:85-92.

Silke J, Rickard J, Gerlic M. The diverse role of RIP kinases in necroptosis and inflammation. Nat.Immunol.2015; 16, 689–697.

Smith C, Farrah T, Goodwin R. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation and death. Cell.1994;76, 959 - 962.

Stanger B, Leder P, Lee T, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes.Cell death, Cell. 1995; 81: 513-523.

Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012; 148: 213–227.

Tanzer M, Tripaydonis A, Webb A, Young S, Varghese L, Hall C et al. Necroptosis signalling is tuned by phosphorylation of MLKL residues outside the pseudokinase domain activation loop. Biochem. J. 2015;471:255–265.

Vitner Е, Salomon Р, Farfel-Becker Т, Meshcheriakova А, Ali М, Klein А et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med. 2014; 20: 204-208.

Wang K, Wang K-Y, Zhang H-Z, Meng X-Y, Chen J-F, Wang P .Up-Regulation of RIP3 Alleviates Prostate Cancer Progression by Activation of RIP3/MLKL Signaling Pathway and Induction of Necroptosis. Front Oncol. 2020; 10: 1720.

Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008; 133: 693–703.

Won K,Min S, Song J, Lim S and Han S-A. Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer. J Breast Cancer. 2021; 24(1): 34–48.

Yang C, Li J, Yu L, Zhang Z, Xu F, Jiang L et al. Regulation of RIP3 by the transcription factor Sp1 and the epige-netic regulator UHRF1 modulates cancer cell necroptosis. Cell Death Dis. 2017; 8(10):e3084.

Yang ZH, Wu XN, He P, Wang X, Wu J, Ai T et al. A non-canonical PDK1-RSK signal diminishes pro-caspase-8-mediated necroptosis blockade. Mol Cell. 2020;80:296–10.e296.

Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol. 2010;7:243–249.

Zhao Q, Guo J, Cheng X, Liao Y, Bi Y, Gong Y et al. RIPK3 Suppresses the Progression of Spontaneous Intestinal Tumorigenesis. Front Oncol. 2021; 11: 664927.

Zhou W and Juan J. Necroptosis in health and diseases. Seminars in Cell & Developmental Biology.2014; (35):14-23.

Калчев К. Експресия на маркер за некроптоза RIP3 в случаи на простатен карцином. Варна; 2020.

Стефанова Н. Експресия на маркери за автофагия и некроптоза при дебелочревен карцином. Варна; 2017.

Стоева М. Имунохистохимична експресия на маркера за некроптоза RIPK3 при карцином на млечната жлеза. Варна; 2022.



Font Size